Key points are not available for this paper at this time.
Bispecific T cell engagers are a promising class of therapeutic proteins for cancer therapy. Their potency and small size often come with systemic toxicity and short half-life, making intravenous administration cumbersome. These limitations can be overcome by tumor-specific
Building similarity graph...
Analyzing shared references across papers
Loading...
Patrick C. Freitag
Jonas Kolibius
Ronja Wieboldt
University of Zurich
University of Basel
University Hospital of Basel
Building similarity graph...
Analyzing shared references across papers
Loading...
Freitag et al. (Wed,) studied this question.
www.synapsesocial.com/papers/68e67e23b6db643587607f4a — DOI: https://doi.org/10.1016/j.omton.2024.200821
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: